Drug intelligence / Profile preview

MDG2012

Development stage: Preclinical
Lead developer: MediGene
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

MDG2012 is an investigational autologous T cell receptor-engineered T cell (TCR-T) therapy targeting the KRAS G12V mutation presented by HLA-A*03. It is being developed by Medigene for the treatment of solid tumors. The therapy leverages a highly specific, sensitive, and safe (3S) TCR platform designed to recognize and eliminate cancer cells harboring the KRAS G12V mutation in the context of HLA-A*03. As of August 2024, MDG2012 remains in preclinical development with lead selection expected in 2025[1][4][6][10].

Targets

KRAS G12V/HLA-A*03:01 (KRAS G12V peptide-HLA-A*03:01 complex)

Beyond the preview

Go deeper on MDG2012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDG2012.

Explore the full profile